The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel StatementVasilios G. Athyros, Christos S. Mantzoros, Theodore K. Alexandrides et al.|Metabolism|2017Cited by 251
“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL SubclassesDimitri P. Mikhailidis, Evangelos Liberopoulos, Klaus G. Parhofer et al.|Current Vascular Pharmacology|2011Cited by 197
Are the Effects of Tamoxifen on the Serum Lipid Profile Modified by Apolipoprotein E Phenotypes?Moses Elisaf, Sonia-Athena P. Karabina, Alexandros D. Tselepis et al.|Oncology|2002Cited by 25
A PAF‐acetylhydrolase activity in <i>Tetrahymena pyriformis</i> cellsAlexandros D. Tselepis, Demokritos Tsoukatos|FEBS Letters|1991Cited by 15
Synthesis of Novel Nilotinib Analogues and Biological Evaluation of Their Antiplatelet Activity and Functionality towards Cancer Cell Proliferation In VitroLouisa Pechlivani, Alexandros D. Tselepis|Pharmaceuticals|2024Cited by 7